Adcock Ingram Holdings Ltd. is a pharmaceutical company, which engages in the manufacture, marketing, and distribution of healthcare products to both private and public sectors of the market. The company is headquartered in Midrand, Gauteng. The company went IPO on 2008-08-25. The firm manufactures, markets, and distributes a range of healthcare and consumer products, and is a supplier to the private sector. Its segments include Consumer, Over the Counter (OTC), Prescription, Hospital, and Other. The Consumer segment is engaged mainly in the fast-moving consumer goods (FMCG) space. The OTC segment focuses on brands sold predominantly in pharmacies. The Prescription segment markets products prescribed by medical practitioners, and specialized instruments and surgical products. Its Hospital segment supplies hospital and critical care products, including intravenous solutions, blood collection products, and renal dialysis systems. The Other segment includes shared services and other support services, including regulatory services in India, as well as the investment in the joint venture and cash and bank overdraft balances, which are managed on a central basis in Southern Africa.
최신 재무제표(Form-10K)에 따르면, KORU Medical Systems Inc의 총 자산은 $0이며, 순손실입니다.
AIHLF의 주요 재무 비율은 무엇인가요?
KORU Medical Systems Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Adcock Ingram Holdings Ltd의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
KORU Medical Systems Inc 주요 수익원은 Domestic Core이며, 최신 수익 발표에서 수익은 27,992,436입니다. 지역별로는 United States이 KORU Medical Systems Inc의 주요 시장이며, 수익은 30,238,333입니다.
Adcock Ingram Holdings Ltd은 수익성이 있나요?
no, 최신 재무제표에 따르면 KORU Medical Systems Inc의 순손실은 $0입니다.